SK Biopharmaceuticals Launches U.S. Market Entry Platform for Korean Life Sciences Companies

Business Korea is reporting that SK Biopharmaceuticals will expand its support for Korean pharmaceutical and biotechnology companies seeking to establish a presence in the U.S., opening a shared business and advisory platform designed to help companies navigate regulatory, clinical, and commercial challenges.

The South Korean drugmaker announced that 31 companies have been selected to participate in SK Life Science LinX, an open-innovation initiative housed at the U.S. headquarters of its subsidiary, SK Life Science. The platform, which opened in June, is now moving into full operation.

Located in the US, LinX provides office space, meeting facilities, and other infrastructure for companies looking to establish local operations and develop relationships with potential U.S. partners. However, SK Biopharmaceuticals intends for the initiative to extend well beyond providing a physical business address.

Through collaboration with the Korea Trade-Investment Promotion Agency (KOTRA)-led K-Bio Global Innovation LinX consortium, participating companies will have access to customized consulting, industry expertise, and introductions to potential business partners. The New Jersey-New York chapter of the Korean-American Society in Biotech and Pharmaceuticals (KASBP) will also contribute its network of local specialists, including professionals with experience in FDA regulations and intellectual property.

The program will concentrate on five areas considered critical to establishing a U.S. presence: FDA regulatory pathways, company formation and taxation, intellectual property and patent strategy, clinical development and technology transfer, and business development.

Support will be tailored to individual company requirements following an assessment of each participant’s business challenges. One-on-one advisory sessions will connect companies with relevant U.S. institutions and industry experts. Additional programming will cover investment opportunities, market-entry planning, visa requirements, accounting, and tax considerations.

SK Biopharmaceuticals also plans to organize partnering activities around major international pharmaceutical and biotechnology events, creating opportunities for participants to connect with U.S. companies. Training in technology presentations and business development will further prepare companies to pursue collaborations and commercial agreements.

A key component of the initiative will be the practical experience SK Biopharmaceuticals has gained bringing its own drug to the U.S. market. The company developed cenobamate, marketed in the US as Xcopri, and managed the process from early drug development through FDA approval and direct commercialization. That experience provides a foundation for advising other Korean companies on the clinical, regulatory, and commercial considerations involved in launching an internally developed drug in the United States.

The 31 selected participants represent several segments of the life sciences industry. Fourteen are pharmaceutical companies, eight specialize in digital healthcare, six are platform technology developers, and three are medical device companies. Their areas of focus include gene therapy, obesity treatments, antibody-drug conjugate (ADC) technologies, drug discovery and evaluation platforms, remote rehabilitation software, and risk-prediction solutions.

The LinX initiative is part of SK Biopharmaceuticals’ broader strategy to build international partnerships and advance open innovation. The company is also pursuing collaborations involving AI-enabled drug discovery, technical advisory services, and technology transfers involving preclinical-stage drug candidates.

For more information, visit www.skbp.com.